Second Genome inks microbiome deal with Pfizer
By Michael Fitzhugh
Thursday, May 1, 2014
Second Genome Inc. is partnering with Pfizer Inc. on a large observational study exploring the relationship between the trillions of microorganisms comprising the human microbiome and obesity and metabolic disorders.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.